Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pressure BioSciences, Inc.    PBIO

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets

Pressure Biosciences : Pressure BioSciences, Inc. Upgraded by EdgeWater Research Partners LLC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/27/2006 | 04:48pm CET

Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that in an update to an initial research report on the Company, EdgeWater Research Partners LLC (?EdgeWater?) has upgraded PBI's rating from a 4 to a 6 and re-established a 12-18 month price target. Of the 20 companies currently covered by EdgeWater, only one has a rating greater than 6.

Copies of the updated and initial research reports on PBI can be obtained free of charge by contacting Mr. David Lavigne at EdgeWater (www.edgewaterresearch.com or 303-593-2877).

Analyst Coverage Disclaimer

Pressure BioSciences is announcing the availability of EdgeWater's updated research report solely for convenience. Any opinions, estimates, or forecasts regarding Pressure BioSciences' historical or predicted performance or operations, including predictions of stock price, made by EdgeWater are theirs alone and do not represent opinions, judgments, estimates, or forecasts of Pressure BioSciences or its management. Pressure BioSciences does not endorse, adopt, or concur with information, conclusions, or recommendations in either EdgeWater's initial or updated research reports on the Company. Pressure BioSciences subscribes for EdgeWater's newsletter and research information, and has purchased EdgeWater's research reports. For the past two years, Pressure BioSciences has paid a fee of $8000 to attend and present at EdgeWater's fall Micro/Small Cap Conference for Investment Professionals.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006; in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005; and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com


© Business Wire 2006
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PRESSURE BIOSCIENCES, INC.
11/21 PRESSURE BIOSCIENCES : Findings on Escherichia coli Reported by Investigators at..
11/14 PRESSURE BIOSCIENCES, INC. : Reports Third Quarter 2017 Financial Results and Pr..
11/13 PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
11/13 PRESSURE BIOSCIENCES, INC. : to Discuss Third Quarter 2017 Financial Results and..
11/01 PRESSURE BIOSCIENCES : Initiates Aggressive Marketing and Sales Strategy Expecte..
10/30 HOW PRESSURE BIOSCIENCES IS REDEFINI : The Promise of New Drugs and Cures, High ..
10/26 NETWORKNEWSWIRE : Releases Exclusive Audio Interview with Pressure BioSciences I..
10/24 PRESSURE BIOSCIENCES INC : Pressure BioSciences, Inc. Discusses Market Opportuni..
10/23 PRESSURE BIOSCIENCES : PBIO) Engages NetworkNewsWire for Corporate Communication..
10/18 PRESSURE BIOSCIENCES : and Phasex Announce Strategic Collaboration Addressing Br..
More news
Managers
NameTitle
Richard T. Schumacher President, CEO, Secretary & Treasurer
Jeffrey N. Peterson Chairman
Joseph Luis Damasio Chief Financial Officer & VP-Finance
Edmund Y. Ting Senior Vice President-Engineering
Vito J. Mangiardi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PRESSURE BIOSCIENCES, INC.4
MEDTRONIC PLC13.81%109 999
BAXTER INTERNATIONAL43.26%34 946
C R BARD INC48.14%24 205
ZIMMER BIOMET HOLDINGS INC9.86%22 983
HOYA CORPORATION12.90%19 208